Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]

QR Code

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]

Lozano R, Domeque N, Apesteguia AF. Clinical Pharmacology: Advances and Applications. 2013;5(1):153–159. On page 155, "Deriving Michaelis–Menten’s equation,26 View original paper by Lozano R, Domeque N, Apesteguia AF

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Lozano R, Domeque N, Apesteguia AF
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2013
Sujets:	Therapeutics. Pharmacology RM1-950
Accès en ligne:	https://doaj.org/article/5b06dddba05b4e019fa00366bcc1ae84
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
par: Lozano R, et autres
Publié: (2013)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
par: Frost C, et autres
Publié: (2018)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
par: Cui Y, et autres
Publié: (2014)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
par: Persson PB
Publié: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
par: Frost C, et autres
Publié: (2014)

ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulations
par: Pavan Vaddady, et autres
Publié: (2021)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
par: Tompson DJ, et autres
Publié: (2014)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
par: Nagelschmitz J, et autres
Publié: (2014)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
par: Cui Y, et autres
Publié: (2013)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein&ndash;Barr virus disease
par: Heather&nbsp;E Vezina, et autres
Publié: (2009)

A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation
par: Siun Kim, et autres
Publié: (2021)

A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
par: Kalman DS, et autres
Publié: (2015)

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
par: Matsumoto K, et autres
Publié: (2016)

Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin – a model-based study
par: Edrich T, et autres
Publié: (2015)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
par: Xia Pu, et autres
Publié: (2021)

Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation
par: Saeed Alqahtani, et autres
Publié: (2021)

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
par: Helen Humphries, et autres
Publié: (2021)

Pharmacokinetics and skin-tissue penetration of daptomycin in rats
par: Matsumoto K, et autres
Publié: (2015)

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
par: Wang X, et autres
Publié: (2013)

Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
par: Rambiritch V, et autres
Publié: (2016)

Population pharmacokinetics of olprinone in healthy male volunteers
par: Kunisawa T, et autres
Publié: (2014)

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
par: Patel C, et autres
Publié: (2011)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
par: Frost C, et autres
Publié: (2018)

Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study
par: François Riglet, et autres
Publié: (2020)

Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling
par: Heajin Jun, et autres
Publié: (2020)

Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin
par: Tjandrawinata RR, et autres
Publié: (2015)

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics
par: Mohamed A. Kamal, et autres
Publié: (2021)

Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically‐based pharmacokinetic model
par: Khaled Abduljalil, et autres
Publié: (2021)

Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma
par: Li Zhang, et autres
Publié: (2021)

Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision‐making—A workshop summary
par: Daphney Jean, et autres
Publié: (2021)

A first‐in‐human study of KMRC011, a potential treatment for acute radiation syndrome, to explore tolerability, pharmacokinetics, and pharmacodynamics
par: Eunsol Yang, et autres
Publié: (2021)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
par: Upreti VV, et autres
Publié: (2013)

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers
par: Farr SJ, et autres
Publié: (2015)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
par: Ekaterina Gibiansky, et autres
Publié: (2021)

Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms
par: Hermann R, et autres
Publié: (2014)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
par: Chetan Rathi, et autres
Publié: (2021)

Mechanisms and the clinical relevance of complex drug–drug interactions
par: Roberts AG, et autres
Publié: (2018)

Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study
par: Yi Tao, et autres
Publié: (2021)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX&reg; mesalamine. [Corrigendum]
par: Nanda K, et autres
Publié: (2013)

Corrigendum to: ‘Rituximab prevents and reverses cardiac remodeling by depressing B cell function in mice’ [Biomed. Pharmacother. 114 (2019) 108804]
par: Xiao-Lei Ma, et autres
Publié: (2021)